Clinical research
While some may wonder about the commercial future of these late-to-the-market solutions, the developers themselves are taking a long view.
This week, the U.S. Food and Drug Administration accepted Investigational New Drug Applications for multiple companies, clearing the way for clinical development.
CytoDyn announced two separate stories about its drug leronlimab today, one for nonalcoholic steatohepatitis and the other for metastatic triple-negative breast cancer.
An announcement lit up the global grapevine today as Clene Nanomedicine released the results from Phase II of their RESCUE-ALS clinical trial.
The drug makers have until February 28, 2022 to review their findings and analytical processes for the drug they are developing to treat relapsed and/or refractory multiple myeloma.
Centessa showed positive early results from its Phase I Part B study on a potential drug that could direct mutation activity in patients with a particular gene that can cause liver and lung diseases.
The decision made VUITY the very first and only eye drop to be approved for the Presbyopia treatment. Follow the article to know aspects of this new treatment.
The FDA informed Moderna that it would need more time to evaluate the company’s Emergency Use Authorization (EUA) submission for its COVID-19 vaccine for adolescents 12 to 17 years of age.
Inovio shares are down about 2% in premarket trading after cancellation reports of a DNA cancer vaccine collab with AstraZeneca.
Researchers found that those who took either the once-a-month or once-every-two-month doses experienced longer periods before relapsing.
PRESS RELEASES